Clinical trials: HEPATITIS C VIRUS CHRONIC INFECTION
Hepatitis C
Clinical Study With Silymarin in the Patients With Chronic Hepatitis C Infection Who Failed Conventional Antiviral Therapy
The purpose of this study is to determine the effectiveness of silymarin 700 mg thrice daily and assess the safety in patients with hepatitis C virus infection compared to a placebo.
- Trial name
- NCT01258686
- Testing
- Silymarin
- Where
- South Korea
- Volunteers
- 53 people
- Sponsor
- Bukwang Pharmaceutical
Hepatitis C, Chronic
Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2
The aim of the study is to confirm efficacy and safety of treatment with 600 mg of BID BI 207127 in combination with 120 mg QD FDV and RBV for 16 or 24 weeks in target chronically infected HCV GT1b treatment naïve patients…
- Trial name
- NCT01728324
- Testing
- Ribavirin: 24-week treatment, BI 207127: 24-week treatment, Faldaprevir: 24-week treatment
- Where
- 109 sites in United States, Australia and 10 more
- Volunteers
- 496 people
- Sponsor
- Boehringer Ingelheim
Hepatitis C, Chronic
An Observational Study to Assess the Effect of Cumulative Ribavirin Dose in Participants With Chronic Hepatitis C
The purpose of this open-label, non-randomized, single-arm, multicentre observational study is to investigate the influence of the cumulative dose (total administered dose/ planned dose) of ribavirin on the sustained virologic…
- Trial name
- NCT02557646
- Testing
- Peginterferon alfa-2a, Ribavirin
- Where
- 27 sites in Hungary
- Volunteers
- 697 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis C Virus Infection
Prospective Cohort Study: To Provide Evidence & Guidance in Hepatitis C Virus Screening, Comparing the New Birth Cohort Recommendations From the CDC, Versus Classical Traditional Strategies With Established Risk Factors
Although infection with the hepatitis C virus (HCV) can result in acute hepatitis; it more commonly progresses to chronic hepatitis. The acute process is most often asymptomatic. Acute HCV typically leads to chronic infection.
- Trial name
- TPEGHCVS (NCT01813266)
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Intermountain Health Care, Inc.
Hepatitis C, Chronic, Insulin Resistance
Study of Response in Chronic Hepatitis C (CHC) Participants Genotype 1 With Insulin Resistance and Prolonged Treatment Duration in Late Responders (P04823/MK-4031-303)
This is a Phase 3b/4, prospective, open-label, randomized, multicenter study of peginterferon alfa-2b plus ribavirin in participants with chronic hepatitis C, genotype 1.
- Trial name
- NCT00493805
- Testing
- Combination of pegylated interferon alfa-2b and ribavirin
- Volunteers
- 59 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis c
The Effect Of DAAs on miRNA-122 And Insulin Resistance In Chronic HCV Patients
The hepatitis C virus is a major cause of chronic liver diseases, including cirrhosis and hepatocellular carcinoma, and infects approximately 3 % of the world population (150-170 million).
- Trial name
- NCT03687229
- Testing
- A)microribonucleic acid-122(miRNA-122), B) Hepatitis C virus Real Time Polymerase chain Reaction (HCV RT-PCR), A)fasting serum glucose, B)Fasting serum insulin
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Assiut University
Hepatitis C
Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin
Part A: The purpose of this study is to evaluate the safety and tolerability of INX-08189 and placebo with Peginterferon alfa-2a and Ribavirin during 12 weeks of treatment Part B: The purpose of this study is to evaluate the…
- Trial name
- NCT01425970
- Testing
- INX-08189, Pegylated interferon alfa-2a, Ribavirin
- Where
- 6 sites in United States
- Volunteers
- 210 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C
A Follow up Study Designed to Obtain Long Term Data on Participants Who Either Achieved a Sustained Virologic Response or Did Not Achieve a Sustained Virologic Response in an AbbVie Sponsored Hepatitis C Study
A follow-up study to assess resistance and durability of response to 3 experimental drugs ABT-450/r, ABT-267, and ABT-333 in participants who have participated in AbbVie Phase 2 or 3 clinical studies with these agents for the…
- Trial name
- NCT01773070
- Testing
- ABT-450/ritonavir, ABT-333, ABT-267
- Volunteers
- 478 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Chronic Hepatitis C
Effect of ASV and DCV Therapy on the Quality of Immune Status in Chronic HCV Patients
Rationale: Chronic HCV infection is characterised by a weak HCV specific CD8+ T cell response, due to continuous pressure of high viral load.
- Trial name
- ImmunoDual (NCT02282709)
- Testing
- Daclatasvir, asunaprevir
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- Foundation for Liver Research
Chronic Hepatitis C Infection
SOF Plus DCV in Treating Chinese Treatment-experienced HCV Patients
For those chronic hepatitis C patients, who are interferon-ineligible or intolerant, there is a burning need for the development of pan-oral interferon-free regimen.
- Trial name
- NCT02473211
- Testing
- Sofosbuvir, Daclatasvir
- Where
- 2 sites in China
- Volunteers
- 106 people
- Sponsor
- Humanity and Health Research Centre
Chronic Hepatitis C Infection
The Role of FGL2-FcgammaRIIB Inhibitory Pathway in Human Viral Hepatitis
Viral hepatitis is a serious world health problem affecting over 1 billion people worldwide. Presently the lack of highly effective treatments results in many patients requiring liver transplantation or death.
- Trial name
- NCT01711164
- Where
- Canada
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Chronic Hepatitis C
Pioglitazone on Viral Kinetics, Cytokines and Innate Immunity in Insulin Resistant CHC GT 1 Subjects
The purpose of this study is to determine if rosiglitazone, a medicine used to treat diabetes, improves response to anti-viral treatment.
- Trial name
- NCT00926016
- Testing
- Pioglitazone (Actos)
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Brooke Army Medical Center
Hepatitis C
Dose Escalation Study of Interleukin-7 (IL-7) and Bitherapy in Asiatic HCV Patients Resistant to Bitherapy
This study is designed to evaluate the safety of biological active dose of a new experimental drug, IL-7, in combination with standard bi-therapy in Asiatic patients with Hepatitis C chronic infection identified as non responders…
- Trial name
- ECLIPSE 3 (NCT01024894)
- Testing
- Interleukin-7
- Where
- 4 sites in Taiwan
- Volunteers
- 15 people
- Sponsor
- Cytheris SA
Hepatitis C, Chronic, Hepacivirus
Adherence in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04281)(COMPLETED)
Patients receiving a patient assistance program during therapy for Hepatitis C will be enrolled into this study. All patients will receive PegIntron pen and Rebetol according to label and the patient assistance program.
- Trial name
- NCT00704522
- Testing
- Peginterferon alfa-2b (SCH 54031), Ribavirin (SCH 18908), Patient assistance program
- Volunteers
- 601 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C Virus (HCV) Infection
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Renally Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection
The purpose of this study is to assess the efficacy and safety of 12 weeks of treatment with the ABT-493/ABT-530 combination regimen in adults with chronic HCV genotype 1 - 6 infection and chronic severe renal impairment.
- Trial name
- EXPEDITION-4 (NCT02651194)
- Testing
- ABT-493/ABT-530
- Volunteers
- 104 people
- Sponsor
- AbbVie
Chronic Liver Disease and Cirrhosis, Liver Cancer
"Constitution of a Biological Collection to Establish Preclinical Translational Models for the Study of Tumors and Chronic Liver Diseases".
Development of preclinical translational models for chronic liver tumors and diseases study, such as spheroids cultured in autologous medium and murine xenograft models to test the efficacy of new therapeutic strategies.
- Conditions
- Chronic Liver Disease and Cirrhosis, Liver Cancer, Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis
- Trial name
- LivMOD (NCT04690972)
- Testing
- Blood sample during surgery, Taking an additional biopsy, Blood sample during diagnostic test
- Where
- France
- Volunteers
- 800 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Hepatitis C, Chronic
Simplifying HCV Treatment in Rwanda for Elsewhere in the Developing World: Pangenotypic and Retreatment Study (SHARED3)
The main purpose of the study is to determine the antiviral efficacy and evaluate the safety and tolerability of sofosbuvir/ velpatasvir (SOF/VEL) and sofosbuvir/ velpatasvir/ voxilaprevir (SOF/VEL/VOX) used to treat individuals…
- Trial name
- SHARED3 (NCT03888729)
- Testing
- sofosbubir/velpatasvir, sofosbubir/velpatasvir/voxilaprevir
- Where
- Rwanda
- Volunteers
- 100 people
- Sponsor
- Partners in Health
Hepatitis C
A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy
The purpose of this research study is to find out the effect of the investigational drug NOV-205 on the level of hepatitis C virus in the blood and whether NOV-205 is well-tolerated at different doses when taken by subjects with…
- Trial name
- NOV-205 (NCT01058512)
- Testing
- NOV-205
- Where
- 6 sites in United States
- Volunteers
- 22 people
- Sponsor
- Cellectar Biosciences, Inc.
Hepatitis C
Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin
Substudy C: The purpose of this substudy is to determine whether Lambda combined with Ribavirin and Daclatasvir for 12 weeks is efficacious in treatment naïve subjects with genotype 1b chronic HCV infection
- Trial name
- D-LITE (NCT01795911)
- Testing
- Pegylated Interferon Lambda, Ribasphere, Daclatasvir
- Where
- United States
- Volunteers
- 165 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C, Chronic
Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin in Participants With/Without Substitution Therapy (P05255)
Although injection drug users represent the majority of new and existing cases of infection with hepatitis C virus (HCV), many lack access to treatment because of concerns about adherence, effectiveness, and reinfection.
- Trial name
- NCT00725751
- Testing
- Pegylated interferon alfa-2b (PegIFN-2b), Ribavirin
- Volunteers
- 353 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.